Press releases
- Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
- Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
- Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
- Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
- Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
- Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
- Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
- Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
- Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
More ▼
Key statistics
As of last trade, Poseida Therapeutics Inc (2RZ:DUS) traded at 2.48, 74.37% above the 52 week low of 1.42 set on Jun 29, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.48 |
---|---|
High | 2.48 |
Low | 2.48 |
Bid | 2.63 |
Offer | 2.69 |
Previous close | 2.48 |
Average volume | 0.00 |
---|---|
Shares outstanding | 96.96m |
Free float | 70.13m |
P/E (TTM) | -- |
Market cap | 289.90m USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 11:30 BST.
More ▼